loading
Cognition Therapeutics Inc stock is traded at $0.634, with a volume of 217.49K. It is up +0.00% in the last 24 hours and down -21.98% over the past month. Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.6399
Open:
$0.6399
24h Volume:
217.49K
Relative Volume:
0.03
Market Cap:
$26.59M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.8025
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-11.49%
1M Performance:
-21.98%
6M Performance:
+9.95%
1Y Performance:
-72.65%
1-Day Range:
Value
$0.62
$0.6539
1-Week Range:
Value
$0.6001
$0.6998
52-Week Range:
Value
$0.34
$2.95

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
Name
Cognition Therapeutics Inc
Name
Phone
412-481-2210
Name
Address
2403 SIDNEY STREET, PITTSBURGH
Name
Employee
25
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
CGTX's Discussions on Twitter

Compare CGTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CGTX
Cognition Therapeutics Inc
0.6399 26.59M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.11 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
716.52 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
653.67 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
275.93 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.25 28.75B 3.30B -501.07M 1.03B -2.1146

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Upgrade B. Riley Securities Neutral → Buy
Jul-30-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-03-21 Initiated B. Riley Securities Buy
Nov-03-21 Initiated Oppenheimer Outperform

Cognition Therapeutics Inc Stock (CGTX) Latest News

pulisher
Feb 06, 2025

Investors in cash trouble should check out Cognition Therapeutics Inc (CGTX) - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating - Marketscreener.com

Feb 06, 2025
pulisher
Feb 05, 2025

Cognition Therapeutics Inc (CGTX) receives a Buy rating from B. Riley Securities - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

What technical indicators reveal about CGTX stock - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Can Cognition Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle

Feb 04, 2025
pulisher
Feb 03, 2025

Is Now The Time To Buy Cognition Therapeutics Inc (NASDAQ: CGTX) Stock? - Stocks Register

Feb 03, 2025
pulisher
Feb 02, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update - Defense World

Feb 02, 2025
pulisher
Jan 30, 2025

A Data-Based Look At Cognition Therapeutics Inc (CGTX) - Stocks Register

Jan 30, 2025
pulisher
Jan 30, 2025

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

CGTXCognition Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy - The Bakersfield Californian

Jan 30, 2025
pulisher
Jan 30, 2025

New Dementia Drug Achieves Remarkable 91% Reduction in Cognitive FluctuationsPhase 2 Results Revealed - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

Brokers Issue Forecasts for CGTX FY2024 Earnings - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

Cognition Therapeutics (NASDAQ:CGTX) Raised to “Strong-Buy” at Brookline Capital Management - Defense World

Jan 29, 2025
pulisher
Jan 23, 2025

70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve

Jan 23, 2025
pulisher
Jan 18, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Alzheimer's Disease Clinical and Non-Clinical Studies, Key - openPR

Jan 15, 2025
pulisher
Jan 15, 2025

**Cognition Therapeutics (NASDAQ:CGTX) Prepares to Advance Treatment Efforts** ** - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Dry Age Macular Degeneration Pipeline Insights 2024: Therapies, Clinical Trials, Therapies and Key Companies involved by DelveInsight |Janssen R&D, Belite Bio, Katairo, Cognition Therapeutics - Barchart

Jan 14, 2025
pulisher
Jan 14, 2025

Dry Age Macular Degeneration Pipeline Insights 2024: - openPR

Jan 14, 2025
pulisher
Jan 13, 2025

Cognition Therapeutics Shows Promising Phase 2 Study Results - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Cognition Therapeutics Is Targeting A Critical Form Of Dementia - Nasdaq

Jan 13, 2025
pulisher
Jan 08, 2025

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan

Jan 08, 2025
pulisher
Jan 02, 2025

Cognition Therapeutics (NASDAQ:CGTX) versus Editas Medicine (NASDAQ:EDIT) Head-To-Head Contrast - Defense World

Jan 02, 2025
pulisher
Dec 24, 2024

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Dec 24, 2024
pulisher
Dec 20, 2024

Cognition Therapeutics Reports Promising Phase 2 Results for Dementia with Lewy Bodies Treatment - Citybuzz

Dec 20, 2024
pulisher
Dec 20, 2024

Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial - Nasdaq

Dec 20, 2024
pulisher
Dec 20, 2024

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely - Simply Wall St

Dec 20, 2024
pulisher
Dec 20, 2024

This Biotech Is Already Off To The Races Before The Opening Bell - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

Cognition Therapeutics Reveals Encouraging Results from Phase 2 COG1201 SHIMMER Study - Defense World

Dec 20, 2024
pulisher
Dec 19, 2024

B. Riley Securities Upgrades Cognition Therapeutics (CGTX) - MSN

Dec 19, 2024
pulisher
Dec 19, 2024

Cognition Therapeutics announces results in Phase 2 study of CT1812 - Yahoo Finance

Dec 19, 2024
pulisher
Dec 19, 2024

TSX 60 Capped Index (TXCI) QuotePress Release - The Globe and Mail

Dec 19, 2024
pulisher
Dec 18, 2024

Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online

Dec 18, 2024
pulisher
Dec 18, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Dec 18, 2024
pulisher
Dec 18, 2024

S&P 500 Health Care [Sector] (SRHC) QuotePress Release - The Globe and Mail

Dec 18, 2024
pulisher
Dec 18, 2024

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? - Benzinga

Dec 18, 2024
pulisher
Dec 18, 2024

TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail

Dec 18, 2024
pulisher
Dec 18, 2024

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire

Dec 18, 2024
pulisher
Dec 18, 2024

Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com

Dec 18, 2024
pulisher
Dec 16, 2024

Cognition Therapeutics Hopes To Affirm CT1812 Holds The Key To Slowing Progression Of Dementia With Lewy Bodies - Nasdaq

Dec 16, 2024
pulisher
Dec 14, 2024

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 - MSN

Dec 14, 2024
pulisher
Dec 13, 2024

Cognition-Enhancing Drugs Market Innovations and Key Players: - openPR

Dec 13, 2024
pulisher
Dec 13, 2024

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Yahoo Finance

Dec 13, 2024
pulisher
Dec 02, 2024

HC Wainwright Has Negative Outlook of CGTX FY2024 Earnings - Defense World

Dec 02, 2024
pulisher
Dec 02, 2024

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Consensus Price Target from Analysts - Defense World

Dec 02, 2024
pulisher
Nov 30, 2024

Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 30, 2024
pulisher
Nov 29, 2024

HC Wainwright Reiterates “Buy” Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World

Nov 29, 2024

Cognition Therapeutics Inc Stock (CGTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cognition Therapeutics Inc Stock (CGTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ricciardi Lisa
CEO & President
Mar 14 '24
Buy
1.75
5,700
9,975
291,345
$80.42
price down icon 0.56%
$20.15
price down icon 2.42%
$349.25
price down icon 1.03%
$4.7595
price down icon 5.75%
biotechnology ONC
$223.24
price down icon 2.49%
$119.25
price down icon 0.68%
Cap:     |  Volume (24h):